###begin article-title 0
RhoA-ROCK and p38MAPK-MSK1 mediate vitamin D effects on gene expression, phenotype, and Wnt pathway in colon cancer cells
###end article-title 0
###begin p 1
###xml 18 35 18 35 <email xmlns:xlink="http://www.w3.org/1999/xlink">amunoz@iib.uam.es</email>
Correspondence to amunoz@iib.uam.es
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 55 56 55 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 66 67 66 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 68 69 68 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 279 280 279 280 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 281 282 281 282 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 359 360 359 360 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 361 362 361 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 401 403 401 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 794 798 794 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 811 816 811 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 874 875 874 875 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 876 877 876 877 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1015 1016 1012 1013 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1017 1018 1014 1015 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
The active vitamin D metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) inhibits proliferation and promotes differentiation of colon cancer cells through the activation of vitamin D receptor (VDR), a transcription factor of the nuclear receptor superfamily. Additionally, 1,25(OH)2D3 has several nongenomic effects of uncertain relevance. We show that 1,25(OH)2D3 induces a transcription-independent Ca2+ influx and activation of RhoA-Rho-associated coiled kinase (ROCK). This requires VDR and is followed by activation of the p38 mitogen-activated protein kinase (p38MAPK) and mitogen- and stress-activated kinase 1 (MSK1). As shown by the use of chemical inhibitors, dominant-negative mutants and small interfering RNA, RhoA-ROCK, and p38MAPK-MSK1 activation is necessary for the induction of CDH1/E-cadherin, CYP24, and other genes and of an adhesive phenotype by 1,25(OH)2D3. RhoA-ROCK and MSK1 are also required for the inhibition of Wnt-beta-catenin pathway and cell proliferation. Thus, the action of 1,25(OH)2D3 on colon carcinoma cells depends on the dual action of VDR as a transcription factor and a nongenomic activator of RhoA-ROCK and p38MAPK-MSK1.
###end p 3
###begin p 4
H.G. Palmer's present address is Institut de Recerca Vall d'Hebron, E-08035 Barcelona, Spain.
###end p 4
###begin p 5
###xml 42 43 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 44 45 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 70 71 70 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 309 312 309 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OCN</italic>
###xml 314 325 314 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">osteocalcin</italic>
###xml 327 330 327 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPN</italic>
###xml 332 343 332 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">osteopontin</italic>
Abbreviations used in this paper: 1,25(OH)2D3, 1,25-dihydroxyvitamin D3; ATF1, activating transcription factor 1; CREB, cAMP response element-binding protein; DKK-1, dickkopf-1; DRB, 5,6-dichlorobenzimidazole riboside; ERK, extracellular signal-regulated kinase; MSK1, mitogen- and stress-activated kinase 1; OCN, osteocalcin; OPN, osteopontin; qRT-PCR, quantitative RT-PCR; PRK2, protein-related kinase 2; ROCK, Rho-associated coiled kinase; shRNA, small hairpin RNA; TCF, T cell factor; VDR, vitamin D receptor; WB, Western blotting.
###end p 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 55 56 55 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 66 67 66 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 68 69 68 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 198 224 198 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">Ord&#243;&#241;ez-Mor&#225;n et al., 2005</xref>
###xml 226 252 226 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">Campbell and Adorini, 2006</xref>
###xml 323 346 323 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">Grant and Garland, 2004</xref>
###xml 348 372 348 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">Giovannucci et al., 2006</xref>
###xml 374 389 374 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">Wu et al., 2007</xref>
###xml 400 401 400 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 402 403 402 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 569 590 569 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">Schwartz et al., 2005</xref>
###xml 592 612 592 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">Agoston et al., 2006</xref>
###xml 614 631 614 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">Deeb et al., 2007</xref>
###xml 642 643 642 643 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 644 645 644 645 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 818 822 818 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 910 929 907 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">P&#225;lmer et al., 2001</xref>
###xml 1154 1179 1151 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">P&#233;rez-Moreno et al., 2003</xref>
###xml 1338 1352 1335 1349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">Takeichi, 1993</xref>
###xml 1446 1449 1440 1443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 1451 1455 1445 1449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AXIN</italic>
###xml 1460 1466 1454 1460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1</italic>
###xml 1537 1542 1528 1533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK-1</italic>
###xml 1544 1549 1535 1540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRPs</italic>
###xml 1554 1557 1545 1548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF</italic>
###xml 1607 1635 1598 1626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">van de Wetering et al., 2002</xref>
###xml 1637 1656 1628 1647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">Sancho et al., 2004</xref>
###xml 1687 1688 1678 1679 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1689 1690 1680 1681 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1985 2004 1964 1983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">P&#225;lmer et al., 2001</xref>
###xml 2006 2023 1985 2002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">Shah et al., 2006</xref>
###xml 2131 2150 2107 2126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">P&#225;lmer et al., 2001</xref>
###xml 2209 2213 2185 2189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 2287 2288 2263 2264 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 2289 2290 2265 2266 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 751 756 <span type="species:ncbi:9606">human</span>
###xml 973 978 <span type="species:ncbi:9606">human</span>
The active vitamin D metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) is a pleiotropic hormone with broad regulatory effects on the proliferation, differentiation, and survival of many cell types (Ordonez-Moran et al., 2005; Campbell and Adorini, 2006). On the basis of extensive epidemiological and preclinical evidence (Grant and Garland, 2004; Giovannucci et al., 2006; Wu et al., 2007), 1,25(OH)2D3 and several less calcemic derivatives are currently under clinical study alone or in combination as potential agents against colorectal cancer and other neoplasias (Schwartz et al., 2005; Agoston et al., 2006; Deeb et al., 2007). 1,25(OH)2D3 inhibits the proliferation and promotes the differentiation to a normal adhesive epithelial phenotype of human colon cancer cells through the transcriptional activation of CDH1 gene encoding E-cadherin and the antagonism of the Wnt-beta-catenin signaling pathway (Palmer et al., 2001), which is aberrantly activated in >80% of human colorectal cancers. E-cadherin is the critical component of the adherens junctions, the intercellular structure needed for the correct formation of compact epithelial layers (Perez-Moreno et al., 2003). Loss of E-cadherin expression is a requisite for cell deadhesion and migration during the epithelial to mesenchymal transition and is common in carcinomas (Takeichi, 1993). Activation of the Wnt-beta-catenin pathway by mutation of intracellular components such as APC, AXIN, or CTNNB1/beta-catenin genes or epigenetic alteration of Wnt inhibitors such as DKK-1, SFRPs, or WIF is the initial step in colorectal tumorigenesis (van de Wetering et al., 2002; Sancho et al., 2004). The interference of 1,25(OH)2D3 with the Wnt-beta-catenin pathway relies on the rapid induction of vitamin D receptor (VDR)-beta-catenin complexes that titrate out beta-catenin, thus hampering formation of the transcriptional competent beta-catenin-T cell factor (TCF) complexes that regulate genes involved in tumorigenesis (Palmer et al., 2001; Shah et al., 2006). Linked to E-cadherin induction, beta-catenin later relocates from the nucleus to the adherens junctions (Palmer et al., 2001). In contrast, the mechanisms leading to the induction of CDH1/E-cadherin and the drastic reorganization of the cytoskeleton by 1,25(OH)2D3 remain unknown.
###end p 7
###begin p 8
###xml 8 9 8 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 10 11 10 11 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 275 276 275 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 277 278 277 278 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 479 480 479 480 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 481 482 481 482 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 746 772 746 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">Sutton and MacDonald, 2003</xref>
###xml 783 784 783 784 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 785 786 785 786 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1051 1070 1051 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">P&#225;lmer et al., 2003</xref>
###xml 1152 1153 1152 1153 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1154 1155 1154 1155 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1325 1326 1325 1326 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1327 1328 1327 1328 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1394 1412 1394 1412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">Losel et al., 2003</xref>
###xml 1414 1433 1414 1433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">Norman et al., 2004</xref>
###xml 857 862 <span type="species:ncbi:9606">human</span>
1,25(OH)2D3 binds to and activates a member of the superfamily of nuclear receptors, the VDR, which is present in >30 cell types and acts as a ligand-modulated transcription factor regulating gene expression (genomic action). The current model for gene activation by 1,25(OH)2D3-VDR predicts that unliganded VDR bound to regulatory sequences (vitamin D response elements) in target genes represses their transcription by recruiting corepressors and histone deacetylases. 1,25(OH)2D3 induces a conformational change in VDR that results in the replacement of corepressors by coactivators and an increased histone acetylase activity, which decondenses chromatin, thus allowing gene activation by the basal RNA polymerase II transcription machinery (Sutton and MacDonald, 2003). 1,25(OH)2D3 drastically alters the gene expression profile of many cell types: in human SW480-ADH colon carcinoma cells it regulates >200 genes involved in cell proliferation, differentiation, survival, invasiveness, and metastatic potential and also in basic cell functions (Palmer et al., 2003). Additionally, rapid, transcription-independent (nongenomic) actions of 1,25(OH)2D3 on cytosolic kinases, phosphatases, phospholipases, or membrane ion channels have been described, although their role and relevance for the anticancer action of 1,25(OH)2D3 and their relation to the genomic effects are poorly understood (Losel et al., 2003; Norman et al., 2004).
###end p 8
###begin p 9
###xml 63 64 63 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 65 66 65 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 85 90 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 158 159 158 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 160 161 160 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 178 199 178 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">Vaisanen et al., 2005</xref>
###xml 221 223 221 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 364 365 364 365 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 366 367 366 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 511 515 511 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 732 733 729 730 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 734 735 731 732 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 849 851 846 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 870 872 867 869 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 873 876 870 873 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
Here we demonstrate that transcriptional activation by 1,25(OH)2D3 of E-cadherin and CYP24, which is its most responsive target gene that encodes the 1,25(OH)2D3 24-hydroxylase (Vaisanen et al., 2005), is mediated by a Ca2+-dependent transient activation of the small GTPase RhoA and its immediate effector Rho-associated coiled kinase (ROCK). Thereafter, 1,25(OH)2D3 activates the p38MAPK and its target the mitogen- and stress-activated kinase 1 (MSK1). Activity of these kinases is required for induction of CDH1/E-cadherin transcription and the acquisition of an adhesive epithelial phenotype and for the inhibition of beta-catenin-TCF transcriptional activity. Our results indicate that the gene regulatory activity of 1,25(OH)2D3 and its antiproliferative and prodifferentiation effects depend on the early, nongenomic increase in cytosolic Ca2+ concentration ([Ca2+]cyt) and the subsequent activation of RhoA-ROCK and p38MAPK-MSK1.
###end p 9
###begin title 10
Results
###end title 10
###begin title 11
###xml 8 9 8 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 10 11 10 11 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 22 24 22 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
1,25(OH)2D3 induces Ca2+ influx and activates RhoA
###end title 11
###begin p 12
###xml 106 135 106 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">Burridge and Wennerberg, 2004</xref>
###xml 206 207 206 207 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 208 209 208 209 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 238 239 238 239 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 240 241 240 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 451 466 451 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, A and B</xref>
###xml 626 627 626 627 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 628 629 628 629 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 752 772 752 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">Maekawa et al., 1999</xref>
###xml 818 833 818 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, C and D</xref>
As the Rho family of GTPases are key regulators of cytoskeleton dynamics and cell adhesion and migration (Burridge and Wennerberg, 2004), we examined their role in the phenotypic changes induced by 1,25(OH)2D3 in SW480-ADH cells. 1,25(OH)2D3 caused a transient activation of RhoA, as measured by the increase in the level of RhoAGTP, but not of Rac or Cdc42, without affecting the RNA (unpublished data) or protein expression of any of these GTPases (Fig. 1, A and B). Other hormones acting through nuclear receptors such as estrogen, retinoic acid, or dexamethasone had no effect on RhoA activity (unpublished data). 1,25(OH)2D3 transiently increased the phosphorylation of cofilin, a downstream ROCK effector involved in cytoskeleton reorganization (Maekawa et al., 1999), but not of protein-related kinase 2 (PRK2; Fig. 1, C and D).
###end p 12
###begin p 13
###xml 8 9 8 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 10 11 10 11 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 0 44 0 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1,25(OH)<sub>2</sub>D<sub>3</sub> activates the RhoA&#8211;ROCK pathway.</bold>
###xml 91 92 91 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 93 94 93 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 229 230 227 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 249 250 247 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 251 252 249 250 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 391 392 389 390 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 393 394 391 392 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 547 548 545 546 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 549 550 547 548 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 730 731 726 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
1,25(OH)2D3 activates the RhoA-ROCK pathway. (A) SW480-ADH cells were treated with 1,25(OH)2D3 for the indicated times and RhoA activity was determined by GST pulldown. Normalized RhoAGTP levels are expressed as the mean +/- SD (n = 3). (B) 1,25(OH)2D3 does not modulate Rac or Cdc42. Levels of active Rac (RacGTP) and Cdc42 (Cdc42GTP) were determined by GST pulldown in cells after 1,25(OH)2D3 addition. (C) Scheme of biochemical routes triggered by RhoAGTP and sites of inhibition by C3 exoenzyme and Y27632. (D) Cells were treated with 1,25(OH)2D3 for the indicated times and the level of phosphocofilin (p-cofilin) and phospho-PRK2 (p-PRK2) were determined by WB. Normalized p-cofilin levels are expressed as the mean +/- SD (n = 3). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
###end p 13
###begin p 14
###xml 89 91 89 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 103 124 103 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Sakurada et al., 2003</xref>
###xml 143 144 143 144 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 145 146 145 146 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 182 184 182 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 224 247 224 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">Losel and Wehling, 2003</xref>
###xml 265 267 265 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 268 271 268 271 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 320 321 320 321 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 322 323 322 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 356 358 356 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 359 362 359 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 461 462 461 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 463 464 463 464 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 478 486 478 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 511 513 511 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 580 582 580 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 594 602 594 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 676 678 676 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 724 726 724 726 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 853 872 853 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">P&#225;lmer et al., 2001</xref>
###xml 883 884 883 884 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 885 886 885 886 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 920 922 920 922 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 923 926 923 926 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 998 1000 998 1000 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1001 1004 1001 1004 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 1031 1039 1031 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 C</xref>
###xml 1068 1070 1068 1070 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1071 1074 1071 1074 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 1132 1140 1132 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 C</xref>
###xml 1234 1236 1234 1236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1237 1240 1237 1240 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 1246 1254 1246 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 C</xref>
###xml 1300 1302 1300 1302 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1418 1442 1418 1442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Huhtakangas et al., 2004</xref>
###xml 1597 1599 1597 1599 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1600 1603 1600 1603 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 1644 1645 1644 1645 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1646 1647 1646 1647 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1666 1668 1666 1668 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1669 1672 1669 1672 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 1722 1730 1722 1730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 D</xref>
###xml 1799 1800 1799 1800 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1801 1802 1801 1802 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1809 1811 1809 1811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1812 1815 1812 1815 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 1842 1844 1842 1844 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1958 1959 1958 1959 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1960 1961 1960 1961 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1981 1983 1981 1983 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2025 2033 2025 2033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 E</xref>
###xml 2092 2094 2092 2094 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2117 2118 2117 2118 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 2150 2152 2150 2152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2192 2194 2192 2194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2195 2198 2195 2198 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 2200 2208 2200 2208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 F</xref>
###xml 2218 2220 2218 2220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2271 2272 2271 2272 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 2273 2274 2273 2274 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 2458 2473 2458 2473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, G and H</xref>
###xml 2578 2579 2578 2579 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 2580 2581 2580 2581 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 2597 2599 2597 2599 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 2612 2614 2612 2614 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 2629 2630 2627 2628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2700 2701 2696 2697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2794 2796 2790 2792 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2797 2800 2793 2796 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 2849 2865 2845 2861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 [A and C]</xref>
###xml 2950 2952 2946 2948 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2953 2956 2949 2952 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 2994 2995 2990 2991 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 2996 2997 2992 2993 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1691 1694 <span type="species:ncbi:10116">rat</span>
Next, we explored a possible link between activation of RhoA, which in some systems is Ca2+ dependent (Sakurada et al., 2003), and the 1,25(OH)2D3-induced changes in intracellular Ca2+ levels reported in several cell types (Losel and Wehling, 2003). The resting [Ca2+]cyt was relatively high in SW480-ADH cells. 1,25(OH)2D3 induced a marked increase in [Ca2+]cyt as registered in individual cells by fluorescence imaging, which was sustained as long as 1,25(OH)2D3 was present (Fig. 2 A). Removal of external Ca2+ abolished this increase, whereas its readdition induced a small Ca2+ overshoot (Fig. 2 B). This finding indicates that the effect was caused the maintenance of Ca2+ entry rather than the transient release of Ca2+ from intracellular stores. In SW480-R cells, derived from the same parental line as SW480-ADH but expressing very little VDR (Palmer et al., 2001), 1,25(OH)2D3 induced a much lower, delayed [Ca2+]cyt rise that was difficult to distinguish from the gradual increase in [Ca2+]cyt in vehicle-treated cells (Fig. 2 C). The slight increase in [Ca2+]cyt in SW480-R cell cultures was caused by only a few cells (Fig. 2 C). Moreover, VDR knockdown by means of small hairpin RNA (shRNA) abolished the increase in [Ca2+]cyt (see Fig. 8 C). These results indicate that VDR mediates Ca2+ influx. However, although the presence of small amounts of VDR in caveolae has been postulated in some cell types (Huhtakangas et al., 2004), we did not detect VDR at the plasma membrane by immunofluorescence. Furthermore, incubation with an anti-VDR antibody did not affect the increase in [Ca2+]cyt (unpublished data). Remarkably, 1,25(OH)2D3 also increased [Ca2+]cyt in the nontumoral rat intestine IEC18 cell line (Fig. 2 D). We explored a possible association between the effects of 1,25(OH)2D3 on [Ca2+]cyt and RhoA. Incubation in Ca2+-free medium abolished the activation of RhoA by its reported activator lysophosphatidic acid and also by 1,25(OH)2D3, indicating that Ca2+ influx was required for RhoA activation (Fig. 2 E). Nimodipine, an antagonist of the L-type voltage-gated Ca2+ channels, but not LaCl3, which blocks store-operated Ca2+ channels, prevented the increase of [Ca2+]cyt (Fig. 2 F). Both Ca2+ influx and RhoA activation are nongenomic 1,25(OH)2D3 effects, as they were not affected by preincubation with the general transcription inhibitor actinomycin D or the RNA polymerase II inhibitor 5,6-dichlorobenzimidazole riboside (DRB; Fig. 2, G and H; and Fig. S1, available at ). Although the relative abundance of responsive cells was larger at 1,25(OH)2D3 doses of 4 x 10-7 M than at 10-7 M (68 +/- 8%, n = 157 cells studied in five independent experiments, vs. 50 +/- 12%, n = 101 cells studied in three independent experiments), no differences in the increase of [Ca2+]cyt was found at the individual cell level (compare Fig. 2 [A and C] with Fig. S1). The lack of effect of the glucocorticoid hormone dexamethasone on [Ca2+]cyt supported the specificity of 1,25(OH)2D3 action (Fig. S1).
###end p 14
###begin p 15
###xml 8 9 8 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 10 11 10 11 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 22 24 22 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1,25(OH)<sub>2</sub>D<sub>3</sub> induces Ca<sup>2+</sup> influx in SW480-ADH cells.</bold>
###xml 155 156 155 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 157 158 157 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 166 168 166 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 218 220 218 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 221 224 221 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 481 482 479 480 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 483 484 481 482 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 529 531 527 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 569 570 567 568 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 571 572 569 570 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 598 600 596 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 601 604 599 602 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 747 748 743 744 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 749 750 745 746 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 795 797 791 793 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 798 801 794 797 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 1122 1123 1118 1119 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1124 1125 1120 1121 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1294 1295 1288 1289 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1296 1297 1290 1291 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1383 1385 1377 1379 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1459 1460 1451 1452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1545 1546 1535 1536 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1577 1578 1567 1568 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1579 1580 1569 1570 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1597 1599 1587 1589 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1806 1807 1792 1793 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1808 1809 1794 1795 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1823 1825 1809 1811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1983 1984 1967 1968 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1985 1986 1969 1970 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 2067 2068 2049 2050 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
1,25(OH)2D3 induces Ca2+ influx in SW480-ADH cells. (A) SW480-ADH cells were loaded with fura2/AM, perfused with external medium, and treated with 1,25(OH)2D3 (4 x 10-7 M) or vehicle at the times indicated, and the [Ca2+]cyt was estimated by fluorescence imaging. Records are mean +/- SEM of 19-27 cells representative of six independent experiments. Insets show fluorescence images coded in pseudocolor of fura2/AM-loaded SW480-ADH cells before and after stimulation with 1,25(OH)2D3. (B) Cells were incubated in normal or in Ca2+-free medium and treated with 1,25(OH)2D3 as indicated. Data of [Ca2+]cyt are the mean +/- SEM of 19 cells representative of three independent experiments. (C) SW480-ADH and SW480-R cells were incubated with 1,25(OH)2D3 or vehicle as indicated. The increase in [Ca2+]cyt (right) corresponds to the maximum detected along the stimulation period for 211 and 169 individual cells studied in six independent experiments for each cell type. The mean increase in untreated cells during a similar period was subtracted. (D) IEC18 cells were loaded with fura2/AM and treated with vehicle or 1,25(OH)2D3 as indicated. Records are mean +/- SEM of 33 and 28 cells, respectively, representative of two independent experiments. (E) SW480-ADH cells were incubated with 1,25(OH)2D3, lysophosphatidic acid (LPA), or the corresponding vehicle for 1 h in normal or in Ca2+-free medium. Normalized RhoAGTP levels are expressed as the mean +/- SD (n = 3). (F) SW480-ADH cells were incubated with 1 muM nimodipine (left) or 20 muM LaCl3 (right) and then with 1,25(OH)2D3 as indicated. Ca2+ measurements are mean +/- SEM of 24 cells representative of two independent experiments. (G) Cells were preincubated with 2 mug/ml actinomycin D (ActD; left) or 75 muM DRB (right) for 30 min before 1,25(OH)2D3 treatment. Ca2+ measurements are mean +/- SEM of 30 cells representative of three independent experiments. (H) Cells were treated with ActD or DRB as in G, and with 1,25(OH)2D3 or vehicle for 1 h. Normalized RhoAGTP levels are expressed as the mean +/- SD (n = 3). **, P < 0.01; ***, P < 0.001.
###end p 15
###begin title 16
###xml 102 103 102 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 104 105 104 105 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
RhoA-ROCK activation mediates the induction of phenotypic change and E-cadherin expression by 1,25(OH)2D3
###end title 16
###begin p 17
###xml 48 49 48 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 50 51 50 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 123 131 123 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 251 252 251 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 253 254 253 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 256 264 256 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 313 314 313 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 315 316 315 316 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 541 559 541 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">Wiese et al., 1992</xref>
###xml 754 762 754 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 C</xref>
###xml 825 838 825 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">Glotzer, 2005</xref>
###xml 840 848 840 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 D</xref>
###xml 899 900 899 900 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 901 902 901 902 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1011 1019 1011 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 1024 1032 1024 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 C</xref>
###xml 1098 1099 1098 1099 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1100 1101 1100 1101 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1251 1259 1251 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 D</xref>
###xml 1340 1341 1340 1341 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1342 1343 1342 1343 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1353 1361 1353 1361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 D</xref>
###xml 1452 1481 1452 1481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">Burridge and Wennerberg, 2004</xref>
###xml 1516 1517 1516 1517 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1518 1519 1518 1519 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1547 1566 1547 1566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">P&#225;lmer et al., 2003</xref>
###xml 1577 1578 1577 1578 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1579 1580 1579 1580 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1871 1872 1871 1872 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1873 1874 1873 1874 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 2001 2002 2001 2002 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 2003 2004 2003 2004 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 2006 2014 2006 2014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 2300 2301 2300 2301 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 2302 2303 2302 2303 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 2410 2411 2410 2411 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 2412 2413 2412 2413 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
To study the role of RhoA activation in 1,25(OH)2D3 activity, we first used the C3 exoenzyme transferase, a Rho inhibitor (Fig. 1 C). C3 exoenzyme altered the morphology of untreated cells and blocked the induction of an adhesive phenotype by 1,25(OH)2D3 (Fig. 3 A). To confirm the involvement of RhoA in 1,25(OH)2D3 activity we generated SW480-ADH cells stably expressing the dominant-negative mutant N19-RhoA (Fig. S2, available at ). Expression of HA-tagged N19-RhoA did not affect posttranscriptional up-regulation of VDR by its ligand (Wiese et al., 1992; Fig. S2). Likewise, it did not change the predominant nuclear localization of VDR (unpublished data). N19-RhoA cells showed a more rounded, less adherent phenotype than mock-transfected cells (Fig. 3 C) and defects in cytokinesis that lead to polynucleated cells (Glotzer, 2005; Fig. 3 D). The induction of epithelioid islands by 1,25(OH)2D3 was impaired in N19-RhoA cell cultures and it was also reduced by treatment with the ROCK inhibitor Y27632 (Fig. 1 C and Fig. 3 C). Immunofluorescence and confocal microscopy showed that 1,25(OH)2D3 induced the progressive translocation of RhoA from the cytosol to the cell periphery and its colocalization with actin filaments in SW480-ADH cells (Fig. 3 D). Both expression of N19-RhoA and treatment with Y27632 inhibited these 1,25(OH)2D3 effects (Fig. 3 D). Consistent with the role of the RhoA-ROCK pathway in modulating the actin cytoskeleton (Burridge and Wennerberg, 2004) and with the increase by 1,25(OH)2D3 of actin-binding proteins (Palmer et al., 2003), 1,25(OH)2D3 induced (claudin-7) and redistributed (claudin-7 and occludin) tight junction proteins in a RhoA-ROCK-dependent manner (Fig. S2). Y27632 partially disrupted the strong adhesive phenotype of cells stably expressing an exogenous E-cadherin gene (SW480-ADH-E-cadherin) irrespective of 1,25(OH)2D3 addition, whereas it did not alter the morphology of E-cadherin and VDR-negative SW480-R cells that do not respond to 1,25(OH)2D3 (Fig. 3 B). In contrast, neither the C3 exoenzyme nor Y27632 altered the level of E-cadherin expression in SW480-ADH-E-cadherin cells (Fig. S2). This finding implicates ROCK in E-cadherin-dependent intercellular adhesion. Moreover, Y27632 also altered the adhesive phenotype and impeded 1,25(OH)2D3 action in the more differentiated HT29 colon carcinoma cells, in which RhoA was also activated by 1,25(OH)2D3 as revealed by the increase in phosphocofilin (unpublished data).
###end p 17
###begin p 18
###xml 85 86 85 86 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 87 88 87 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 0 89 0 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RhoA&#8211;ROCK activation is necessary for the induction of adhesive phenotype by 1,25(OH)<sub>2</sub>D<sub>3</sub>.</bold>
###xml 205 206 204 205 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 207 208 206 207 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 407 408 406 407 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 409 410 408 409 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 621 622 618 619 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 623 624 620 621 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 326 331 <span type="species:ncbi:10090">mouse</span>
RhoA-ROCK activation is necessary for the induction of adhesive phenotype by 1,25(OH)2D3. (A) Phase-contrast microscopy of cells pretreated with 2 mug/ml of C3 exoenzyme for 2 h and incubated with 1,25(OH)2D3 or vehicle for an additional 24 h. (B) Phase-contrast microscopy of both SW480-ADH cells stably expressing exogenous mouse E-cadherin (SW480-ADH-E-cadherin) and SW480-R cells incubated with 1,25(OH)2D3 or vehicle in the presence or absence of 10 muM Y27632 for 48 h. (C) Phase-contrast micrographs of mock cells pretreated for 4 h with 10 muM Y27632 or vehicle and of N19-RhoA cells upon incubation with 1,25(OH)2D3 or vehicle for 48 h. (D) Confocal laser microscopy images of mock and N19-RhoA cells treated as in C. Costaining for the localization of RhoA (green) and F-actin (red). Merged images are also shown. All scanned, phase-contrast, and confocal microscopy images are representative of at least three independent experiments. Bars, 10 mum.
###end p 18
###begin p 19
###xml 76 77 76 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 78 79 78 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 123 124 123 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 125 126 125 126 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 156 164 156 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 185 193 185 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 221 229 221 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 C</xref>
###xml 309 324 309 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, D and E</xref>
###xml 377 385 377 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 F</xref>
###xml 506 507 506 507 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 508 509 508 509 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 633 634 633 634 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 635 636 635 636 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 667 675 667 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 G</xref>
Next we examined whether RhoA-ROCK controls E-cadherin induction by 1,25(OH)2D3. The increase of E-cadherin RNA by 1,25(OH)2D3 was reduced by C3 exoenzyme (Fig. 4 A) in N19-RhoA cells (Fig. 4 B) or by addition of Y27632 (Fig. 4 C). The same results were obtained when E-cadherin protein levels were analyzed (Fig. 4, D and E) and on the activation of E-cadherin gene promoter (Fig. 4 F). Collectively, these results indicate that RhoA-ROCK activation is required for the induction of E-cadherin by 1,25(OH)2D3. Accordingly, Y27632 and N19-RhoA inhibited the accumulation of E-cadherin protein at the adherens junctions after 1,25(OH)2D3 treatment of SW480-ADH cells (Fig. 4 G).
###end p 19
###begin p 20
###xml 87 88 87 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 89 90 89 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 0 91 0 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RhoA&#8211;ROCK activation is required for the induction of E-cadherin expression by 1,25(OH)<sub>2</sub>D<sub>3</sub>.</bold>
###xml 204 205 203 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 206 207 205 206 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 339 340 338 339 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 341 342 340 341 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 504 505 502 503 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 506 507 504 505 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 807 808 803 804 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 809 810 805 806 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 904 905 898 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 968 969 962 963 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 970 971 964 965 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1102 1103 1094 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1338 1339 1330 1331 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1340 1341 1332 1333 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1374 1375 1364 1365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1594 1595 1584 1585 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1596 1597 1586 1587 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1211 1216 <span type="species:ncbi:9606">human</span>
RhoA-ROCK activation is required for the induction of E-cadherin expression by 1,25(OH)2D3. (A) SW480-ADH cells were pretreated with 2 mug/ml of C3 exoenzyme or vehicle for 2 h before addition of 1,25(OH)2D3 or vehicle (4 h), and the level of E-cadherin RNA was determined by qRT-PCR. (B) Mock and N19-RhoA cells were treated with 1,25(OH)2D3 as indicated and the level of E-cadherin RNA was determined as in A. (C) SW480-ADH cells were pretreated or not with 10 muM Y27632 for 4 h and then with 1,25(OH)2D3 or vehicle for an additional 4 h, and the level of E-cadherin RNA was determined as in A. The data in A-C are expressed as the mean +/- SD (three independent experiments performed in triplicate). (D) SW480-ADH cells were pretreated with C3 exoenzyme (2 h) and then incubated with vehicle or 1,25(OH)2D3 for an additional 20 h, and the level of E-cadherin protein was assessed by WB. Mean +/- SD (n = 3). (E) Mock and N19-RhoA cells were incubated with 1,25(OH)2D3 or vehicle (24 h) in the presence or absence of Y27632, and the expression of E-cadherin protein was assessed by WB. Mean +/- SD (n = 3). (F) Mock and N19-RhoA cells were transiently transfected with the plasmid encoding a fragment of the human E-cadherin gene promoter. After overnight incubation they were treated with Y27632 (4 h) and then incubated with 1,25(OH)2D3 or vehicle (48 h). Mean +/- SD (n = 3); r.l.u., relative luciferase units. (G) Confocal laser microscopy images showing the immunolocalization of E-cadherin in mock cells pretreated or not with Y27632 (4 h) and in N19-RhoA cells incubated with 1,25(OH)2D3 or vehicle (48 h). Bar, 10 mum. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
###end p 20
###begin title 21
###xml 68 69 68 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 70 71 70 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
RhoA-ROCK activation mediates the gene regulatory action of 1,25(OH)2D3
###end title 21
###begin p 22
###xml 65 66 65 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 98 103 98 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 223 228 223 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 254 255 254 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 256 257 256 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 318 333 318 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, A and B</xref>
###xml 422 427 422 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 433 441 433 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 491 492 491 492 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 493 494 493 494 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 517 528 517 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">osteopontin</italic>
###xml 530 533 530 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPN</italic>
###xml 536 547 536 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">osteocalcin</italic>
###xml 549 552 549 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OCN</italic>
###xml 559 564 559 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A</italic>
###xml 632 636 628 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CIP1</sup>
###xml 673 692 669 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">P&#225;lmer et al., 2001</xref>
###xml 694 720 690 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">Ord&#243;&#241;ez-Mor&#225;n et al., 2005</xref>
###xml 722 743 718 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">Aguilera et al., 2007</xref>
###xml 787 802 783 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, D and E</xref>
###xml 944 952 940 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 F</xref>
###xml 1166 1167 1162 1163 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1168 1169 1164 1165 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1279 1284 1275 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 1382 1383 1378 1379 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1384 1385 1380 1381 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
We also analyzed the role of RhoA-ROCK in the effects of 1,25(OH)2D3 on other targets such as the CYP24 gene. As for E-cadherin, each of the three agents, C3 exoenzyme, N19-RhoA, and Y27632, decreased the activation of the CYP24 gene promoter by 1,25(OH)2D3 in SW480-ADH and in SW480-R cells expressing exogenous VDR (Fig. 5, A and B; unpublished data). Accordingly, N19-RhoA and Y27632 also decreased the accumulation of CYP24 RNA (Fig. 5 C). Moreover, the induction of a series of 1,25(OH)2D3 targets genes such as osteopontin (OPN), osteocalcin (OCN), and CYP3A at the RNA level and integrin alpha3, ZO-1, DICKKOPF-1 (DKK-1), p21CIP1, and paxillin at the protein level (Palmer et al., 2001; Ordonez-Moran et al., 2005; Aguilera et al., 2007) was blunted in N19-RhoA-expressing cells (Fig. 5, D and E). N19-RhoA also inhibited the induction and accumulation of ZO-1 protein at the membrane where it colocalizes with cortical actin filaments (Fig. 5 F). The same result was obtained using Y27632 (unpublished data). Likewise, N19-RhoA and Y27632 inhibited the increase and redistribution of paxillin and the induction of focal contacts and stress fibers by 1,25(OH)2D3 as seen by immunofluorescence (Fig. S3, available at ). Also in HT29 cells, Y27632 inhibited the increase of CYP24 RNA, the induction of E-cadherin and vinculin proteins, and the decrease of cyclin D1 by 1,25(OH)2D3 (unpublished data).
###end p 22
###begin p 23
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 60 61 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 62 63 62 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 0 77 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RhoA&#8211;ROCK mediates the induction of <italic>CYP24</italic> and other 1,25(OH)<sub>2</sub>D<sub>3</sub> target genes.</bold>
###xml 220 225 220 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 392 393 391 392 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 394 395 393 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 503 508 502 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 598 599 597 598 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 600 601 599 600 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 704 705 703 704 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 706 707 705 706 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 835 836 833 834 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 837 838 835 836 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 873 878 871 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 956 957 954 955 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 958 959 956 957 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1040 1045 1037 1042 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 1139 1140 1136 1137 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1141 1142 1138 1139 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1200 1203 1197 1200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPN</italic>
###xml 1205 1208 1202 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OCN</italic>
###xml 1214 1219 1211 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A</italic>
###xml 1422 1423 1417 1418 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1424 1425 1419 1420 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1447 1451 1442 1446 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CIP1</sup>
###xml 1544 1548 1535 1539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CIP1</sup>
###xml 1687 1688 1675 1676 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1689 1690 1677 1678 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1816 1817 1804 1805 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1818 1819 1806 1807 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 214 219 <span type="species:ncbi:9606">human</span>
###xml 497 502 <span type="species:ncbi:9606">human</span>
RhoA-ROCK mediates the induction of CYP24 and other 1,25(OH)2D3 target genes. (A) SW480-ADH and -R cells were transiently cotransfected with a plasmid encoding VDR and with a construct containing a fragment of the human CYP24 promoter-luciferase construct. After overnight incubation the cells were treated with 2 mug/ml of C3 exoenzyme for 2 h as indicated before addition (24 h) of 1,25(OH)2D3 or vehicle. (B) Mock and N19-RhoA cells were transfected with the plasmid encoding a fragment of the human CYP24 promoter-luciferase construct. After overnight incubation they were treated with 1,25(OH)2D3 or vehicle for 6 or 9 h (left). Mock cells were similarly transfected and then incubated with 1,25(OH)2D3 or vehicle in the presence or absence of 10 muM Y27632 for 4 h (right). (C) Mock or N19-RhoA cells were incubated with 1,25(OH)2D3 or vehicle (4 h) and the level of CYP24 RNA was determined by qRT-PCR (left). Mock cells were incubated with 1,25(OH)2D3 or vehicle in the presence or absence of 10 muM Y27632 for 4 h and the level of CYP24 RNA was determined (right). (D) Mock or N19-RhoA SW480-ADH cells were incubated with 1,25(OH)2D3 or vehicle for the indicated times and the expression of OPN, OCN, and CYP3A RNA was determined by qRT-PCR. The data in A-D are expressed as the mean +/- SD (three independent experiments performed in triplicate). (E) Mock or N19-RhoA SW480-ADH cells were incubated with 1,25(OH)2D3 or vehicle for 4 (p21CIP1) or 48 h (all others), and the expression of integrin alpha3, ZO-1, DKK-1, paxillin, and p21CIP1 proteins were determined by WB. Controls: beta-tubulin and -actin. The numbers below tracks represent the fold increase values in 1,25(OH)2D3-treated versus vehicle-treated cells. (F) Confocal laser microscopy images of mock and N19-RhoA cells incubated with 1,25(OH)2D3 or vehicle (48 h) illustrating the localization of ZO-1 (green) and F-actin (red). Bar, 10 mum. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
###end p 23
###begin title 24
###xml 129 130 126 127 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 131 132 128 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
RhoA-ROCK activation mediates the antagonism of the Wnt-beta-catenin pathway and the inhibition of cell proliferation by 1,25(OH)2D3
###end title 24
###begin p 25
###xml 8 9 8 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 10 11 10 11 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 239 258 233 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">P&#225;lmer et al., 2001</xref>
###xml 369 370 360 361 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 371 372 362 363 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 443 451 434 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 574 575 562 563 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 576 577 564 565 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 634 642 622 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 727 728 711 712 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 729 730 713 714 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 817 825 801 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 864 865 848 849 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 866 867 850 851 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1024 1032 1005 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 C</xref>
###xml 1154 1155 1132 1133 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1156 1157 1134 1135 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1253 1261 1231 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 D</xref>
###xml 1311 1312 1289 1290 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1313 1314 1291 1292 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1365 1373 1343 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 D</xref>
1,25(OH)2D3 induces the relocalization of beta-catenin from the nucleus to the plasma membrane adherens junctions, where it binds E-cadherin, thus inhibiting the induction of proliferation and invasion genes by beta-catenin-TCF complexes (Palmer et al., 2001). Coimmunoprecipitation assays revealed that the formation of E-cadherin-beta-catenin complexes after 1,25(OH)2D3 addition was decreased in N19-RhoA cells as compared with mock cells (Fig. 6 A). Concordantly, the redistribution of beta-catenin from the nucleus and cytosol to the plasma membrane induced by 1,25(OH)2D3 was partially inhibited in N19-RhoA cells or by Y27632 (Fig. 6 B). Likewise, alpha- and p120-catenins relocated at the plasma membrane after 1,25(OH)2D3 addition and this effect was also diminished in N19-RhoA cells or by Y27632 addition (Fig. 6 B; unpublished data). Moreover, 1,25(OH)2D3 did not repress the transcriptional activity of beta-catenin-TCF in N19-RhoA cells, whereas it weakly repressed that activity in Y27632-treated mock cells (Fig. 6 C). These results show that RhoA-ROCK activation is required for the antagonism of the Wnt-beta-catenin pathway by 1,25(OH)2D3. In line with the effect of N19RhoA in other systems, N19RhoA cells grew less than mock cells (Fig. 6 D). Additionally, the inhibitory effect of 1,25(OH)2D3 on cell proliferation was lost in N19-RhoA cells (Fig. 6 D).
###end p 25
###begin p 26
###xml 160 161 150 151 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 162 163 152 153 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 0 164 0 154 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RhoA&#8211;ROCK activation mediates the redistribution of &#945;-, &#946;-, and p120-catenins and the inhibition of &#946;-catenin&#8211;TCF transcriptional activity by 1,25(OH)<sub>2</sub>D<sub>3</sub>.</bold>
###xml 221 222 211 212 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 223 224 213 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 747 748 721 722 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 749 750 723 724 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 874 875 847 848 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 876 877 849 850 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1405 1406 1367 1368 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1407 1408 1369 1370 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1622 1623 1578 1579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1686 1687 1642 1643 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1688 1689 1644 1645 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
RhoA-ROCK activation mediates the redistribution of alpha-, beta-, and p120-catenins and the inhibition of beta-catenin-TCF transcriptional activity by 1,25(OH)2D3. (A) Mock and N19-RhoA cells were incubated with 1,25(OH)2D3 for the indicated times and the formation of complexes between E-cadherin and beta-catenin was assessed by coimmunoprecipitation (IP). Cell extracts were first immunoprecipitated using an anti-beta-catenin antibody and the presence of E-cadherin and beta-catenin (as control) in the immunoprecipitates was determined by WB. The IP was repeated four times with similar results. (B) Y27632 and N19-RhoA inhibit the redistribution toward the plasma membrane compartment of alpha-, beta-, and p120-catenins induced by 1,25(OH)2D3. Confocal laser microscopy images of mock (pretreated or not with 10 muM Y27632) and N19-RhoA cells incubated with 1,25(OH)2D3 or vehicle for 48 h. alpha-, beta-, and p120-catenins were stained by immunofluorescence using specific antibodies and F-actin by phalloidin-rhodamine labeling, respectively. The images are representative of at least three independent experiments. Bar, 10 mum. (C) Mock and N19-RhoA SW480-ADH cells were transiently transfected with wild-type (TOP) or mutant (FOP) luciferase-base reporter plasmids for the transcriptional activity of beta-catenin-TCF complexes. After overnight incubation, the cells were treated with 1,25(OH)2D3 or vehicle for 48 h in the presence or absence of 10 muM Y27632 and the intracellular luciferase activity was determined. beta-catenin-TCF transcriptional activity (TOP/FOP ratio) is expressed as the mean +/- SD (n = 3). (D) Mock and N19-RhoA cells were incubated with 1,25(OH)2D3 or vehicle for the indicated times and the number of cells in the cultures was determined. The data represent one out of the four independent experiments performed in triplicate. ***, P < 0.001.
###end p 26
###begin title 27
###xml 42 43 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 44 45 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
p38MAPK and MSK1 are activated by 1,25(OH)2D3 and mediate the induction of E-cadherin and CYP24 gene
###end title 27
###begin p 28
###xml 48 50 48 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 111 112 111 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 113 114 113 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 233 234 233 234 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 235 236 235 236 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 238 246 238 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
###xml 374 375 374 375 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 376 377 376 377 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 379 387 379 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
###xml 580 599 577 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">Davies et al., 2000</xref>
###xml 693 712 690 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">Davies et al., 2000</xref>
###xml 777 778 774 775 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 779 780 776 777 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 830 831 827 828 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 832 833 829 830 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 835 843 832 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
###xml 1056 1076 1047 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">Larriba et al., 2007</xref>
As several PKC isoforms respond to changes in Ca2+ levels, we studied the effects of PKC inhibitors on 1,25(OH)2D3 action (Fig. S4, available at ). Ro318220, but not GF109203X, abrogated the increase of E-cadherin protein by 1,25(OH)2D3 (Fig. 7 A). In addition, phosphorylation of PKD, a substrate of PKC, was decreased by GF109203X and Ro318220 but not affected by 1,25(OH)2D3 (Fig. 7 A; unpublished data), thus implicating one or more Ro318220 target kinases other than the PKC family in E-cadherin induction. The candidates were MAPKAP-K1/RSK, MSK1, PRK2, GSK-3beta, and S6K1 (Davies et al., 2000). S6K1 was ruled out, as rapamycin, which specifically inhibits its upstream regulator mTOR (Davies et al., 2000), did not prevent the increase of E-cadherin protein by 1,25(OH)2D3 (Fig. S4). PRK2 was neither activated by 1,25(OH)2D3 (Fig. 1 D) nor affected by Ro318220 (Fig. S4). GSK-3beta was ruled out as Ro318220 did not increase the level of Snail1 protein, a target of this kinase that accumulates upon GSK-3beta blockade by LiCl in SW480-ADH cells (Larriba et al., 2007; unpublished data).
###end p 28
###begin p 29
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 74 75 74 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 76 77 76 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 0 78 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">p38MAPK and MSK1 mediate the induction of E-cadherin and <italic>CYP24</italic> by 1,25(OH)<sub>2</sub>D<sub>3</sub>.</bold>
###xml 212 213 210 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 214 215 212 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 345 346 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 469 470 463 464 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 471 472 465 466 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 674 675 666 667 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 676 677 668 669 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 839 840 831 832 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 841 842 833 834 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1218 1219 1210 1211 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1220 1221 1212 1213 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1292 1293 1281 1282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1372 1377 1361 1366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 1460 1461 1449 1450 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1462 1463 1451 1452 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1563 1564 1550 1551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1732 1733 1719 1720 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1734 1735 1721 1722 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1848 1849 1833 1834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1121 1126 <span type="species:ncbi:9606">human</span>
p38MAPK and MSK1 mediate the induction of E-cadherin and CYP24 by 1,25(OH)2D3. (A) SW480-ADH cells were pretreated with either vehicle, 3.5 muM GF109203X, or 2 muM Ro318220 for 2 h before incubation with 1,25(OH)2D3 or vehicle for 20 h, and the level of E-cadherin protein and phosphoprotein kinase D (p-PKD) were determined by WB. Mean +/- SD (n = 3). (B) Cells were pretreated with either vehicle, 10 muM H89, or 20 muM Rp-cAMP for 2 h before incubation with 1,25(OH)2D3 for 20 h and E-cadherin protein was determined by WB. Quantification was as in A. (C) Cells were pretreated with either vehicle, 20 muM U0126, or 30 muM SB203580 for 2 h before incubation with 1,25(OH)2D3 or vehicle for 20 h and E-cadherin protein and total and p-ERK1/2 were determined by WB. Quantification was as in A. (D) Cells were incubated (4 h) with 1,25(OH)2D3 or vehicle in the presence or absence of the indicated kinase inhibitor (same doses as in A-C) and E-cadherin RNA was determined by qRT-PCR (three independent experiments performed in triplicate). (E) SW480-ADH cells were transfected with the plasmid encoding a fragment of the human E-cadherin gene promoter. After overnight incubation they were treated (48 h) with 1,25(OH)2D3 or vehicle in the presence or absence of 1 muM Ro318220. Mean +/- SD (n = 3). (F) SW480-ADH cells were incubated and treated as in D and the level of CYP24 RNA was determined and quantificated as in D. (G) Cells were treated with 1,25(OH)2D3 or vehicle and the expression of total and p-p38MAPK and p-MSK1 was determined by WB. Mean +/- SD (n = 3). (H) SW480-ADH cells were transfected with MSK1 or MSK2 siRNA oligonucleotides or with scrambled oligos as control (C). 1 d later cells were treated with 1,25(OH)2D3 or vehicle for an additional 6 h. E-cadherin, MSK1, and MSK2 protein levels were determined by WB. Mean +/- SD (n = 3). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
###end p 29
###begin p 30
###xml 86 88 86 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 90 109 90 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">Davies et al., 2000</xref>
###xml 183 202 183 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">Davies et al., 2000</xref>
###xml 220 228 220 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 B</xref>
###xml 367 384 367 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">Deak et al., 1998</xref>
###xml 386 403 386 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">Dunn et al., 2005</xref>
###xml 572 580 572 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 C</xref>
###xml 656 657 656 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 658 659 658 659 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
We used additional inhibitors: H89, which inhibits PKA, MSK1, and S6K1 with similar IC50 (Davies et al., 2000), decreased E-cadherin induction; and Rp-cAMP, a specific PKA inhibitor (Davies et al., 2000), had no effect (Fig. 7 B). This ruled out PKA and pointed to MSK1. Because MSK1 is activated by either p38MAPK or MKK1-extracellular signal-regulated kinase (ERK; Deak et al., 1998; Dunn et al., 2005), we analyzed the effect of their respective inhibitors, SB203580 and U0126/PD98059. SB203580, but not U0126 or PD98059, decreased the induction of E-cadherin protein (Fig. 7 C; unpublished data), suggesting a role of p38MAPK-MSK1 in mediating 1,25(OH)2D3 action. Furthermore, Ro318220, H89, or SB203580 decreased the phosphorylation of histone H3, an MSK1 substrate (Fig. S4). The link between the activation of p38MAPK and MSK1 was further demonstrated by means of the p38MAPK activator anisomycin, which increased the level of phospho-MSK1 in an SB203580-, H89-, and Ro318220-sensitive manner (Fig. S4).
###end p 30
###begin p 31
###xml 140 148 140 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 D</xref>
###xml 221 229 221 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 E</xref>
###xml 277 282 277 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 358 366 358 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 F</xref>
###xml 432 433 432 433 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 434 435 434 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 490 495 490 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 522 523 522 523 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 524 525 524 525 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 660 665 660 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 677 678 677 678 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 679 680 679 680 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Consistent with these results, Ro318220, H89, or SB203580, but not GF109203X, Rp-cAMP, or U0126, prevented the induction of E-cadherin RNA (Fig. 7 D). Ro318220 also blocked the activation of the E-cadherin gene promoter (Fig. 7 E). Moreover, similar results were obtained with CYP24 gene, except that U0126 and Rp-cAMP repressed the accumulation of its RNA (Fig. 7 F) and PD98059 repressed the activation of the promoter by 1,25(OH)2D3 (Fig. S4). Furthermore, in HT29 cells the increase of CYP24 RNA expression by 1,25(OH)2D3 was inhibited by Ro318220 or SB203580 (unpublished data). These results implicate p38MAPK-MSK1, MKK1-ERK, and PKA in the induction of CYP24 by 1,25(OH)2D3.
###end p 31
###begin p 32
###xml 26 27 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 28 29 28 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 141 149 141 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 G</xref>
###xml 173 174 173 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 175 176 175 176 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 354 362 354 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 B</xref>
###xml 519 520 519 520 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 521 522 521 522 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 531 539 531 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 H</xref>
We confirmed that 1,25(OH)2D3 increased the level of active, phosphorylated p38MAPK and MSK1 without affecting their total cellular content (Fig. 7 G). Furthermore, 1,25(OH)2D3 increased phosphorylation of the transcription factors cAMP response element-binding protein (CREB) and activating transcription factor 1 (ATF1), which are MSK1 substrates (see Fig. 9 B). Finally, the finding that knockdown of MSK1 or MSK2 by siRNA decreased the induction of E-cadherin is further evidence that these kinases mediate 1,25(OH)2D3 action (Fig. 7 H).
###end p 32
###begin title 33
###xml 51 52 51 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 53 54 53 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
The activation of the signaling pathway by 1,25(OH)2D3 requires VDR and takes place in other tumoral and nontumoral cell lines
###end title 33
###begin p 34
###xml 105 106 105 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 107 108 107 108 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 432 433 432 433 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 434 435 434 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 437 445 437 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 A</xref>
###xml 553 561 553 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 B</xref>
###xml 660 665 660 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 734 735 734 735 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 736 737 736 737 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 739 747 739 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 B</xref>
###xml 777 782 777 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 784 787 784 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPN</italic>
###xml 789 792 789 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OCN</italic>
###xml 798 803 798 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A</italic>
###xml 879 880 879 880 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 881 882 881 882 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 903 905 903 905 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 906 909 906 909 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 911 919 911 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 C</xref>
###xml 948 956 948 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 D</xref>
###xml 968 976 968 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 E</xref>
###xml 988 996 988 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 F</xref>
###xml 1075 1083 1075 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 F</xref>
###xml 1194 1195 1194 1195 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1196 1197 1196 1197 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
To examine the dependence on VDR of the different components of the signaling pathway induced by 1,25(OH)2D3, we knocked down VDR expression in SW480-ADH cells by means of infection with VDR shRNA lentiviruses. Two VDR shRNA (3 and 4) and one control shRNA cell lines were generated. Both VDR shRNA lines showed less intercellular adhesion and more rounded cells than control shRNA cells in both the absence and presence of 1,25(OH)2D3 (Fig. 8 A). We confirmed that VDR shRNA cells expressed less basal and induced VDR protein than control shRNA cells (Fig. 8 B). In addition, VDR shRNA cells had a lower level of E-cadherin protein and showed no induction of CYP24 promoter in the absence and particularly in the presence of 1,25(OH)2D3 (Fig. 8 B). Likewise, the induction of CYP24, OPN, OCN, and CYP3A RNA was blunted in VDR shRNA cells (unpublished data). Remarkably, 1,25(OH)2D3 did not increase [Ca2+]cyt (Fig. 8 C) and did not activate RhoA (Fig. 8 D), p38MAPK (Fig. 8 E), or MSK1 (Fig. 8 F) in VDR shRNA cells. Consistently, it did not increased CREB phosphorylation (Fig. 8 F). Together, these results show that VDR is needed for the induction of the whole signaling pathway by 1,25(OH)2D3.
###end p 34
###begin p 35
###xml 93 94 93 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 95 96 95 96 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 0 97 0 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink">VDR knockdown abrogates the induction of nongenomic signaling and gene expression by 1,25(OH)<sub>2</sub>D<sub>3</sub>.</bold>
###xml 203 204 203 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 205 206 205 206 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 311 316 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 412 413 411 412 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 414 415 413 414 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 495 500 491 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 548 554 544 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 606 608 602 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 609 612 605 608 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 632 633 628 629 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 634 635 630 631 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 727 728 723 724 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 729 730 725 726 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 982 983 976 977 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 984 985 978 979 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1115 1116 1107 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1183 1184 1175 1176 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1185 1186 1177 1178 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1285 1286 1275 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1353 1354 1343 1344 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1355 1356 1345 1346 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
VDR knockdown abrogates the induction of nongenomic signaling and gene expression by 1,25(OH)2D3. (A) Phase-contrast images of SW480-ADH cells stably expressing control or VDR shRNA treated with 1,25(OH)2D3 or vehicle for 48 h as indicated. Bar, 10 mum. (B) Expression of VDR and E-cadherin proteins (left) and CYP24 promoter activity (right) in control and VDR shRNA cells that were treated or not with 1,25(OH)2D3 for 24 h. Protein levels were determined by WB using beta-actin as control and CYP24 promoter activity was analyzed as in legend to Fig. 5. (C) Effect of VDR knockdown on the increase in [Ca2+]cyt induced by 1,25(OH)2D3. The three cell types were loaded with fura2/AM and assessed for responsiveness to 1,25(OH)2D3. Traces are mean +/- SEM values of control cells (black) or the two VDR shRNA lines (red and blue traces). Data are representative of at least two independent experiments for each cell line. (D) Control and VDR-4 shRNA cells were treated with 1,25(OH)2D3 or vehicle for 1 h and RhoA activity was determined by GST pulldown. Normalized RhoAGTP levels are expressed as the mean +/- SD (n = 3). (E) Control and VDR-4 shRNA cells were treated with 1,25(OH)2D3 or vehicle for 2 h and the level of phospho- and total p38MAPK was determined by WB (mean +/- SD, n = 3). (F) Control and VDR-4 shRNA cells were treated with 1,25(OH)2D3 or vehicle for 2 h and the level of phospho-MSK1 (p-MSK1) and phospho-CREB (p-CREB) in nuclear (N) and cytosolic (C) fractions was determined by WB. Total CREB and lamin B and beta-tubulin were used as respective controls. *, P < 0.05; ***, P < 0.001.
###end p 35
###begin p 36
###xml 69 70 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 71 72 71 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 394 399 394 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 420 421 420 421 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 422 423 422 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 598 599 598 599 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 600 601 600 601 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 605 608 605 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPN</italic>
###xml 657 662 657 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A</italic>
###xml 705 710 705 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 238 243 <span type="species:ncbi:9606">human</span>
###xml 287 292 <span type="species:ncbi:10090">mouse</span>
###xml 318 321 <span type="species:ncbi:10116">rat</span>
###xml 718 723 <span type="species:ncbi:9606">human</span>
To know whether p38MAPK-MSK1 mediated the genomic effects of 1,25(OH)2D3 in other cell types we used the SB203580 and Ro318220 inhibitors. First, we checked that both agents inhibited efficiently the phosphorylation of CREB in nontumoral human HaCaT keratinocytes and IMR90 fibroblasts, mouse NIH 3T3 fibroblasts, and rat intestine IEC18 cells (Fig. S5, available at ). Next, the activation of CYP24 promoter by 1,25(OH)2D3 was found to be inhibited by Ro318220 or SB203580 in IEC18 and HaCaT and by Ro318220 and H89 in NIH 3T3 cells (Fig. S5). Finally, Ro318220 inhibited the induction by 1,25(OH)2D3 of OPN RNA in IMR90, HaCaT, and NIH 3T3 cells, that of CYP3A RNA in IMR90 and HaCaT cells, and that of CYP24 RNA in human Caco-2 colon and MCF-7 breast cancer cells (Fig. S5).
###end p 36
###begin title 37
###xml 145 146 142 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 147 148 144 145 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
The activation of p38MAPK-MSK1 is a downstream RhoA-ROCK event that is necessary for the interference of the Wnt-beta-catenin pathway by 1,25(OH)2D3
###end title 37
###begin p 38
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 43 46 43 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 66 68 66 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 111 119 111 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 A</xref>
###xml 255 256 255 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 257 258 257 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 342 343 342 343 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 344 345 344 345 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 376 384 376 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 B</xref>
###xml 473 474 473 474 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 475 476 475 476 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 529 537 529 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 B</xref>
###xml 661 662 661 662 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 663 664 663 664 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 786 791 786 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 807 808 807 808 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 809 810 809 810 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 830 845 830 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9, C and D</xref>
Ro318220 did not prevent the rise in [Ca2+]cyt, indicating that Ca2+ influx is independent of MSK1 activation (Fig. 9 A). Likewise, Ro318220 neither inhibited the increase in the level of RhoAGTP (unpublished data) or of phosphorylated cofilin by 1,25(OH)2D3 nor affected phospho-PRK2 (Fig. S4). The activation of p38MAPK and MSK1 by 1,25(OH)2D3 was absent in N19-RhoA cells (Fig. 9 B). In line with this, the level of phosphorylated CREB and ATF1 was increased by 1,25(OH)2D3 in mock cells but did not change in N19-RhoA cells (Fig. 9 B). Concordantly, pretreatment with Y27632 inhibited the increase of phosphorylated p38MAPK, MSK1, CREB, and ATF1 by 1,25(OH)2D3 in SW480-ADH cells (unpublished data). In addition, SB203580 or Ro318220 further reduced the induction of E-cadherin and CYP24 RNA by 1,25(OH)2D3 in N19-RhoA cells (Fig. 9, C and D). Collectively, these results indicate that the p38MAPK-MSK1 module acts downstream of RhoA.
###end p 38
###begin p 39
###xml 35 36 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 37 38 37 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 0 130 0 127 <bold xmlns:xlink="http://www.w3.org/1999/xlink">p38MAPK-MSK1 activation by 1,25(OH)<sub>2</sub>D<sub>3</sub> depends on RhoA&#8211;ROCK and is necessary for the interference of the Wnt&#8211;&#946;-catenin pathway.</bold>
###xml 179 180 176 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 181 182 178 179 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 236 238 232 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 239 242 235 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 272 273 268 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 274 275 270 271 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 403 404 397 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 405 406 399 400 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 529 530 521 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 669 670 659 660 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 671 672 661 662 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 883 884 871 872 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 885 886 873 874 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 955 960 943 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 1220 1221 1205 1206 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1222 1223 1207 1208 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1283 1284 1265 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1340 1341 1322 1323 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1342 1343 1324 1325 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1441 1443 1423 1425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1347 1352 <span type="species:ncbi:9606">human</span>
p38MAPK-MSK1 activation by 1,25(OH)2D3 depends on RhoA-ROCK and is necessary for the interference of the Wnt-beta-catenin pathway. (A) SW480-ADH cells were incubated with 1,25(OH)2D3 in the presence of 2 muM Ro318220 or vehicle. The [Ca2+]cyt was determined after 1,25(OH)2D3 addition. Mean +/- SEM of 28-30 cells (three independent experiments). (B) Mock and N19-RhoA cells were incubated with 1,25(OH)2D3 or vehicle (2 h) and the levels of total and phospho-p38MAPK, -MSK1, -CREB, and -ATF1 were determined by WB. Mean +/- SD (n = 3). (C) Mock and N19-RhoA cells were pretreated with vehicle, 30 muM Ro318220, or 30 muM SB203580 (2 h) and then incubated with 1,25(OH)2D3 for additional 4 h, and the level of E-cadherin RNA was determined by qRT-PCR. Mean +/- SD (three independent experiments performed in triplicate). (D) Mock and N19-RhoA cells were incubated (4 h) with 1,25(OH)2D3 in the presence of vehicle, Ro318220, or SB203580, and the level of CYP24 RNA and quantification was determined as in C. (E) SW480-ADH cells were transfected with wild-type (TOP) or mutant (FOP) reporter plasmids for beta-catenin-TCF activity. After overnight incubation, the cells were treated (48 h) with either vehicle or 1,25(OH)2D3 in the presence or absence of 1 muM Ro318220. Mean +/- SD (n = 3). (F) Scheme of the mechanism of action of 1,25(OH)2D3 in human SW480-ADH cells. A rapid, VDR-dependent nongenomic signaling pathway that starts with Ca2+ influx and continues with the sequential activation of RhoA GTPase and the kinases ROCK, p38MAPK, and MSK1 converges in the nucleus with ligand-activated VDR to regulate gene expression and interfere with the Wnt-beta-catenin pathway leading to proliferation arrest and epithelial differentiation. MSK1 may target VDR and/or its coregulators and/or downstream transcription factors. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
###end p 39
###begin p 40
###xml 116 117 113 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 118 119 115 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 121 129 118 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 E</xref>
###xml 229 230 223 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 231 232 225 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Finally, Ro318220 prevented the inhibition of the transcriptional activity of beta-catenin-TCF complexes by 1,25(OH)2D3 (Fig. 9 E). This indicates that MSK1 also mediates the antagonism of the Wnt-beta-catenin pathway by 1,25(OH)2D3.
###end p 40
###begin title 41
Discussion
###end title 41
###begin p 42
###xml 89 106 89 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">Deeb et al., 2007</xref>
###xml 172 173 172 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 174 175 174 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 199 201 199 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 493 501 490 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9 F</xref>
###xml 510 512 507 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 603 604 600 601 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 605 606 602 603 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Natural and synthetic vitamin D compounds are increasingly studied as anticancer agents (Deeb et al., 2007). Our results highlight a signaling pathway triggered by 1,25(OH)2D3 that starts with the Ca2+ influx from the external medium and continues with the activation of RhoA-ROCK and then of the p38MAPK-MSK1 kinase module. These are necessary steps for the regulation of gene expression, the antagonism of the Wnt-beta-catenin pathway, and the induction of an adhesive epithelial phenotype (Fig. 9 F). The Ca2+ influx-RhoA-ROCK-p38MAPK-MSK1 pathway shown here links the nongenomic and genomic 1,25(OH)2D3 effects and demonstrates that the rapid modulation of ion content and cytosolic GTPases and kinases is required for the regulation of gene expression and cell physiology.
###end p 42
###begin p 43
###xml 329 331 329 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 350 351 350 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 352 353 352 353 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 514 532 514 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">Losel et al., 2003</xref>
###xml 534 553 534 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">Norman et al., 2004</xref>
###xml 768 792 768 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">Zanello and Norman, 2004</xref>
###xml 840 841 840 841 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 842 843 842 843 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 845 864 845 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">Nemere et al., 2004</xref>
###xml 980 981 980 981 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 982 983 982 983 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1013 1031 1013 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">Erben et al., 2002</xref>
###xml 1065 1067 1065 1067 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1172 1173 1172 1173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1174 1175 1174 1175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1183 1185 1183 1185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1527 1545 1527 1545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">Gocek et al., 2007</xref>
###xml 948 952 <span type="species:ncbi:10090">mice</span>
The activation of the nongenomic pathway requires VDR as shown by the generation and study of VDR shRNA cells and the analysis of VDR-deficient SW480-R cells. How these rapid and transcription-independent events are triggered is unclear, as we did not detect VDR at the plasma membrane and an anti-VDR antibody failed to block Ca2+ influx by 1,25(OH)2D3. These negative results do not rule out the presence of small amounts of VDR at the plasma membrane, as occurs with estrogen or progesterone nuclear receptors (Losel et al., 2003; Norman et al., 2004). Moreover, the lack of effect on VDR knockdown by means of shRNA and in VDR-deficient SW480-R cells is consistent with the requirement of functional VDR in osteoblasts for the modulation of ion channel responses (Zanello and Norman, 2004). VDR may not be the only receptor for 1,25(OH)2D3 (Nemere et al., 2004). However, the evidence from studies using cultured cells and genetically modified mice suggests that most 1,25(OH)2D3 actions are mediated by VDR (Erben et al., 2002). We conclude that the initial Ca2+ influx is mediated by cytosolic VDR, although low membrane VDR levels as well as the binding of 1,25(OH)2D3 to a Ca2+ channel or an associated membrane protein cannot be ruled out. The conformational change induced by ligand binding in cytosolic VDR may trigger the initial signal, perhaps indirectly by releasing putative associated factors. The cytosolic fraction of VDR has recently been localized in the vicinity of the plasma membrane in leukemia cells (Gocek et al., 2007), which would tend to support this hypothesis. Our findings imply a dual action of VDR, as a signaling molecule at the plasma membrane-cytosol and as a transcription factor within the nucleus.
###end p 43
###begin p 44
###xml 90 92 90 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 119 120 119 120 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 121 122 121 122 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 253 273 253 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">Morelli et al., 2008</xref>
###xml 414 431 410 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">Wang et al., 2000</xref>
###xml 480 481 476 477 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 482 483 478 479 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 210 215 <span type="species:ncbi:9606">human</span>
###xml 220 223 <span type="species:ncbi:10116">rat</span>
The use of antagonists indicates that L-type voltage-gated calcium channels mediate the Ca2+ influx induced by 1,25(OH)2D3, as it has been recently reported in the case of the vitamin D analogue elocalcitol in human and rat bladder smooth muscle cells (Morelli et al., 2008). Interestingly, the expression of the alpha1c isoform of this channel is elevated in colon cancer as compared with adjacent normal mucosa (Wang et al., 2000), which is compatible with an effect of 1,25(OH)2D3 in this neoplasia.
###end p 44
###begin p 45
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 130 131 130 131 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 132 133 132 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 308 337 308 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">Burridge and Wennerberg, 2004</xref>
###xml 482 483 482 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 484 485 484 485 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 843 861 843 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">Braga et al., 1997</xref>
###xml 863 867 863 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">1999</xref>
###xml 869 887 869 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">Noren et al., 2001</xref>
###xml 889 908 889 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">Braga and Yap, 2005</xref>
###xml 910 924 910 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">Reynolds, 2007</xref>
###xml 949 950 949 950 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 951 952 951 952 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1044 1046 1044 1046 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1047 1050 1047 1050 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 1262 1280 1262 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">Noren et al., 2001</xref>
###xml 1282 1286 1282 1286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">2003</xref>
###xml 1288 1311 1288 1311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">Wildenberg et al., 2006</xref>
The role of RhoA in the induction of CDH1/E-cadherin and other target genes and the profound phenotypic change induced by 1,25(OH)2D3 are consistent with its key function regulating the cytoskeleton, endocytosis, cell polarity, migration, gene transcription, proliferation, differentiation, and oncogenesis (Burridge and Wennerberg, 2004). The inhibitory effects of N19-RhoA and Y27632 on the induction and redistribution of tight junction and adherens junction proteins by 1,25(OH)2D3 indicate that RhoA activation is crucial for the acquisition of polarity and the adhesive phenotype, respectively, which are characteristics of differentiated epithelial cells. Rho GTPases and E-cadherin function control each other: stable localization of E-cadherin at the adherens junctions requires Rho activity, whereas RhoA is inhibited by E-cadherin (Braga et al., 1997, 1999; Noren et al., 2001; Braga and Yap, 2005; Reynolds, 2007). The effect of 1,25(OH)2D3 on RhoA is transient. The rapid activation of RhoA may be a response to the increase in [Ca2+]cyt, whereas the down-regulation may be a consequence of the later accumulation of E-cadherin and p120-catenin at the plasma membrane, as E-cadherin activates and p120-catenin recruits the Rho inhibitor p190RhoGAP (Noren et al., 2001, 2003; Wildenberg et al., 2006). This transient nature of RhoA activation is probably crucial, as we were unable to generate SW480-ADH cells stably expressing constitutively active RhoA caused by cytotoxicity.
###end p 45
###begin p 46
###xml 223 243 223 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">Thomson et al., 1999</xref>
###xml 420 421 420 421 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 422 423 422 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 734 751 734 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">Dunn et al., 2005</xref>
###xml 1035 1054 1035 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">Vicent et al., 2006</xref>
###xml 1203 1204 1203 1204 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1205 1206 1205 1206 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1292 1297 1292 1297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 1424 1425 1421 1422 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1426 1427 1423 1424 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1480 1499 1474 1493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">P&#225;lmer et al., 2001</xref>
###xml 1501 1518 1495 1512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">Shah et al., 2006</xref>
###xml 970 995 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
MSK1, the downstream kinase activated, is predominantly nuclear, although its presence in the cytosol has also been documented, and it participates in the nucleosome response associated with immediate-early gene induction (Thomson et al., 1999). MSK1 may phosphorylate VDR and/or its coregulators or components of any of the multiprotein complexes (DRIP-TRAP and Mediator) involved in transcriptional control by 1,25(OH)2D3-VDR. Perhaps a more plausible role of MSK1 may be the regulation of downstream transcription factors: MSK1 may recruit coactivators or promote interactions with chromatin-modifying or -remodeling complexes through its ability to phosphorylate transcription factors such as CREB or ATF1 or the histone H3 tail (Dunn et al., 2005). Recently, ERK activation by progestins has been reported to cause progesterone receptor phosphorylation and MSK1 activation, which is followed by recruitment of a complex of the three proteins to a nucleosome on the mouse mammary tumor virus promoter and its subsequent induction (Vicent et al., 2006). Putatively, MSK1 (and possibly the 75% homologous MSK2, according to the knockdown experiments) plays similar roles in gene activation by 1,25(OH)2D3. In the case of E-cadherin it depends on p38MAPK-MSK1 activation, but in the case of CYP24 it also depends on MKK1-ERK and PKA. Additionally, the finding that the antagonism of the Wnt-beta-catenin pathway by 1,25(OH)2D3, which is mediated by VDR-beta-catenin interaction (Palmer et al., 2001; Shah et al., 2006), is sensitive to Ro318220 points to effects of MSK1 at the VDR level.
###end p 46
###begin p 47
###xml 96 98 96 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 172 173 172 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 174 175 174 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 218 220 218 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 305 306 305 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 307 308 307 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 594 612 594 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">Jemal et al., 2006</xref>
###xml 434 439 <span type="species:ncbi:9606">human</span>
Our results raise interesting questions such as the role of nuclear versus cytosolic VDR, how Ca2+ can activate RhoA, or which are the MSK1 substrates relevant for 1,25(OH)2D3 action. These questions and whether the Ca2+ influx-RhoA-ROCK-p38MAPK-MSK1 pathway is responsible for or participates in 1,25(OH)2D3 action in other cellular processes will require further work. The identification of this route as crucial for the control of human colon carcinoma cell proliferation and phenotype opens novel possibilities of pharmaceutical intervention for the second most lethal neoplasia worldwide (Jemal et al., 2006).
###end p 47
###begin title 48
Materials and Methods
###end title 48
###begin title 49
Cell culture and transfections
###end title 49
###begin p 50
###xml 95 114 95 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">P&#225;lmer et al., 2001</xref>
###xml 411 432 411 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">Aguilera et al., 2007</xref>
###xml 465 466 465 466 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 467 468 467 468 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 703 704 703 704 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 705 706 705 706 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 731 733 731 733 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;9</sup>
###xml 739 741 739 741 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 772 774 772 774 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 984 991 984 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Firefly</italic>
###xml 1002 1020 1002 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Renilla reniformis</italic>
###xml 1226 1231 1226 1231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 1607 1611 1607 1611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 1686 1705 1686 1705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">P&#225;lmer et al., 2001</xref>
###xml 1921 1924 1918 1921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fos</italic>
###xml 1970 1990 1967 1987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">Korinek et al., 1997</xref>
###xml 8 13 <span type="species:ncbi:9606">human</span>
###xml 180 185 <span type="species:ncbi:9606">human</span>
###xml 233 236 <span type="species:ncbi:10116">rat</span>
###xml 260 265 <span type="species:ncbi:10090">mouse</span>
###xml 330 336 <span type="species:ncbi:9913">bovine</span>
###xml 1002 1020 <span type="species:ncbi:6136">Renilla reniformis</span>
###xml 1220 1225 <span type="species:ncbi:9606">human</span>
Tumoral human SW480-ADH and SW480-R cells (derived from the SW480 cell line by limit dilution [Palmer et al., 2001]), HT29, Caco-2 (colon) and MCF-7 (breast) cells, and nontumoral human IMR90 (fibroblasts) and HaCaT (keratinocytes), rat IEC18 (intestine), and mouse NIH 3T3 (fibroblasts) cells were cultured in DME plus 10% fetal bovine serum (Invitrogen). SW480-ADH-E-cadherin cells were previously described (Aguilera et al., 2007). All experiments using 1,25(OH)2D3 (provided by R. Bouillon and A. Verstuyf, Katholieke Universiteit, Leuven, Belgium, and J.P. van de Velde, Solvay, Weesp, Netherlands) were performed in DME supplemented with charcoal-treated serum. To ensure dose dependence, 1,25(OH)2D3 was used in the range 10-9 to 10-7 M; data shown correspond to 10-7 M unless specified (see Calcium imaging section). Cells were transfected using the jetPEI reagent (PolyPlus Transfection), achieving an efficiency of 60% as judged by fluorescence. In transient transfections, Firefly (Luc) and Renilla reniformis luciferase (Rluc) activities were measured separately using the Dual Luciferase reagent kit (Promega) and a Lumat LB9507 luminometer (Berthold). Luc activity was normalized to the Rluc activity. The human CYP24 promoter (-367/+1 fragment containing two vitamin D response elements at -293/-273 and -172/-143 positions), luciferase reporter, and VDR expression plasmids were a gift from A. Aranda (Instituto de Investigaciones Biomedicas, Madrid, Spain); and the RhoA constructs were obtained from P. Crespo (Instituto de Biomedicina y Biotecnologia de Cantabria, Santander, Spain). The CDH1/E-cadherin promoter activity was studied using the -987-TK-Luc construct (Palmer et al., 2001). To study beta-catenin-TCF transcriptional activity we used the TOP-Flash and FOP-Flash plasmids containing multimerized wild-type (CCTTTGATC) or mutated (CCTTTGGCC) TCF/LEF-1 binding sites upstream of a minimal c-fos promoter driving luciferase gene expression (Korinek et al., 1997; a gift from H. Clevers, Hubrecht Institute and University Medical Center, Utrecht, Netherlands). Mock and N19-RhoA cells were generated by stable transfection of SW480-ADH cells with HA-tagged empty vector or N19-RhoA cDNA and selection with 0.3 mg/ml G418 (Sigma-Aldrich).
###end p 50
###begin title 51
Gene silencing
###end title 51
###begin p 52
###xml 494 499 <span type="species:ncbi:9606">human</span>
To knock down VDR expression, SW480-ADH cells were infected with lentiviral particles containing a U6 promoter driven by an shRNA targeting VDR. These constructs belong to the MISSION TRC-Hs 1.0 shRNA library (Sigma-Aldrich). Infected cells were selected with puromycin at 1 mug/ml. Control cells were infected with lentivirus bearing a nontargeting shRNA that activates the RISC complex and the RNA interference pathway but that contains at least five mismatched nucleotides compared with any human gene (clone SHC002; Sigma-Aldrich). MSK1 and MSK2 siRNA oligonucleotides (siGENOME SMART pool MSK1 and MSK2; Thermo Fisher Scientific) and control oligonucleotides (siControl nontargeting siRNA pool #1; Thermo Fisher Scientific) were transfected using Lipofectamine 2000 in OPTIMEM medium (both from Invitrogen). Transfection efficiency was judged to be >90% using fluorescent-labeled oligonucleotides.
###end p 52
###begin title 53
Inhibitors
###end title 53
###begin p 54
###xml 400 419 397 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">Davies et al., 2000</xref>
###xml 587 588 584 585 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
The inhibitor C3 exoenzyme (Rho) was obtained from Cytoskeleton, Inc.; Ro318220 (PKC, MSK, p70S6K1, PRK2, GSK-3beta, and p90S6K1/RSK1), SB203580 (p38MAPK), GF109203X (PKC), Y27632 (ROCK), H89 (PKA, MSK1, and S6K1), Rp-cAMP (PKA specific), PD98059 and U0126 (MKK1), and rapamycin (mTOR-S6K1) were obtained from EMD. The potency and specificity of these kinase inhibitors have been reported elsewhere (Davies et al., 2000). The transcription inhibitors actinomycin D and DRB, the p38MAPK activator anisomycin, and lysophosphatidic acid were obtained from Sigma-Aldrich. Nimodipine and LaCl3 were obtained from Bayer AG and Sigma-Aldrich, respectively.
###end p 54
###begin title 55
Antibodies
###end title 55
###begin p 56
###xml 245 249 235 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">CIP1</sup>
###xml 537 540 523 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink">133</sup>
###xml 558 561 544 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink">581</sup>
###xml 587 589 573 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink">10</sup>
###xml 16 21 <span type="species:ncbi:10090">mouse</span>
###xml 275 278 <span type="species:ncbi:10116">rat</span>
###xml 349 355 <span type="species:ncbi:9986">rabbit</span>
###xml 678 682 <span type="species:ncbi:9925">goat</span>
We used primary mouse monoclonal antibodies against RhoA and phospho-ERK1/2 (Santa Cruz Biotechnology, Inc.); Cdc42, Rac, E-cadherin, beta- and p120-catenin, PRK2, and paxillin (BD); integrin alpha3 (Millipore); beta-tubulin (Sigma-Aldrich); p21CIP1 (Millipore); HA (Babco); rat monoclonal antibodies against VDR (Millipore) and MSK2 (R&D Systems); rabbit polyclonal antibodies against RhoA, cyclin D1, and ERK2 (Santa Cruz Biotechnology, Inc.); alpha-catenin (Sigma-Aldrich); total and phosphocofilin, phospho-p38MAPK, -S6K1, -CREB (Ser133)/ATF1, -MSK1 (Ser581), -PRK2, -histone H3 (Ser10), and -PKD (Cell Signaling Technology); occludin, ZO-1, and claudin-7 (Invitrogen); and goat polyclonal antibodies against beta-actin, lamin B, MSK1, and DKK-1 (Santa Cruz Biotechnology, Inc.).
###end p 56
###begin title 57
RNA synthesis
###end title 57
###begin p 58
###xml 108 109 107 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
30,000 cells were seeded in 24-well dishes. After overnight incubation, cells were pulsed with 1 muCi/ml [5-3H]uridine 5'-triphosphate (Hartmann Analytic) for 4 h in the presence of the indicated doses of actinomycin D or vehicle (added 30 min before). At the end of the labeling period, the medium was removed and the cells were rinsed twice in PBS and fixed with chilled 10% trichloroacetic acid for 10 min. Trichloroacetic acid was then removed and the monolayers were washed in ethanol and air dried at room temperature for 20 min. Thereafter, precipitated macromolecules were dissolved in 500 mul of 0.5 N NaOH-0.1% SDS and 450 mul of each sample was diluted in 5 ml of scintillation solution OptiPhase HiSafe (PerkinElmer). Radioactivity was measured on a 1209 RackBeta counter (LKB Wallac; PerkinElmer).
###end p 58
###begin title 59
Calcium imaging
###end title 59
###begin p 60
###xml 42 43 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 97 98 85 86 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 233 234 220 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 245 246 232 233 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 300 302 287 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 324 325 311 312 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 604 605 579 580 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 606 607 581 582 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 871 873 846 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 874 877 849 852 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 923 946 898 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">Villalobos et al., 2001</xref>
###xml 957 958 932 933 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 959 960 934 935 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 987 989 962 964 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 1063 1065 1038 1040 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 1102 1104 1077 1079 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1105 1108 1080 1083 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 1164 1172 1139 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
Cells were plated at approximately0.5 x 106 cells/ml on 12-mm glass coverslips treated with poly-l-Lysine and incubated with 4 muM fura2/AM for 60 min at room temperature in external medium containing 145 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM glucose, and 10 mM Hepes/NaOH, pH 7.42. For Ca2+-free conditions, CaCl2 was replaced by 0.5 mM EGTA. Coverslips were then placed on the heated stage (37degreesC) of an inverted microscope (Diaphot [Nikon]; Axiovert S100 TV [Carl Zeiss, Inc.]) and continuously perfused with prewarmed (37degreesC) external medium containing either vehicle or 1,25(OH)2D3. Cells were then epi-illuminated alternately at 340 and 380 nm. Light emitted above 520 nm was recorded with a Magical Image Processor (Applied Imaging) or a camera (Orca-ER ; Hamamatsu Photonics). Pixel by pixel ratios of consecutive frames were captured and [Ca2+]cyt was estimated from these ratios as reported (Villalobos et al., 2001). 1,25(OH)2D3 was usually used at 4 x 10-7 M because the relative abundance of responsive cells is larger than at 10-7 M (see Results). The increase in [Ca2+]cyt was however the same at both doses (compare results in Fig. 2 A and Fig. S1).
###end p 60
###begin title 61
Western blotting (WB) and immunoprecipitation assays
###end title 61
###begin p 62
###xml 151 152 151 152 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 345 346 342 343 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 348 349 345 346 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 701 702 690 691 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 704 705 693 694 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 791 792 779 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 1092 1093 1068 1069 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1095 1096 1071 1072 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 1175 1176 1150 1151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 1563 1574 <span type="species:ncbi:3704">horseradish</span>
Whole-cell extracts were prepared by washing the monolayers twice in PBS and cell lysis was done by incubation in RIPA buffer (150 mM NaCl, 1.5 mM MgCl2, 10 mM NaF, 10% glycerol, 4 mM EDTA, 1% Triton X-100, 0.1% SDS, 1% deoxycholate, and 50 mM Hepes, pH 7.4) plus phosphatase- and protease-inhibitor mixture (25 mM beta-glycerophosphate, 1 mM Na3VO4, 1 mM PMSF, 10 mug/ml leupeptin, and 10 mug/ml aprotinin) for 15 min on ice followed by centrifugation at 13,000 rpm for 10 min at 4degreesC. To obtain subcellular extracts the cells were washed in cold PBS and disrupted using a hypotonic lysis buffer (0.5% NP-40, 10 mM Hepes, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, pH 7.9, 1 mM DDT, 1 mM PMSF, 1 mM Na3VO4, and 10 mug/ml aprotinin, leupeptin, and pepstatin). Lysates were centrifuged 11,000 g for 10 min at 4degreesC, and supernatants containing the cytosolic and membrane protein extract were maintained at -80degreesC until analysis. Pellets containing nuclei were lysed with hypertonic buffer (0.5% NP-40, 20 mM Hepes, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, pH 7.9, 1 mM DDT, 1 mM PMSF, 1 mM Na3VO4, and 10 mug/ml aprotinin, leupeptin, and pepstatin) and centrifuged at 11,000 g at 4degreesC for 6 min, and supernatants were conserved at -80degreesC. The protein concentration was measured using the DC protein assay kit (Bio-Rad Laboratories). WB of cell lysates or immunoprecipitates was performed by electrophoresis in SDS gels and by protein transfer to Immobilon P membranes (Millipore). The membranes were incubated with the appropriate primary and secondary horseradish peroxidase-conjugated antibodies, and the antibody binding was visualized using the ECL detection system (GE Healthcare). Quantification was done by densitometry using ImageJ software.
###end p 62
###begin title 63
GST pull-down assays
###end title 63
###begin p 64
###xml 239 256 239 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">Azim et al., 2000</xref>
###xml 258 280 258 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">Ren and Schwartz, 2000</xref>
###xml 476 493 476 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">Azim et al., 2000</xref>
###xml 495 517 495 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">Ren and Schwartz, 2000</xref>
###xml 311 316 <span type="species:ncbi:9606">human</span>
The activation of RhoA, Rac, and Cdc42 was assessed by affinity precipitation of the GST-bound form of these GTPases using the GST-rhotekin binding domain for RhoA and the GST-CRIB domain of PAK1 for Rac and Cdc42 as described previously (Azim et al., 2000; Ren and Schwartz, 2000). For in vivo binding assays, human cells were washed twice in ice-cold PBS and lysed, incubated with the GST fusion protein on glutathione-Sepharose beads, and analyzed as described previously (Azim et al., 2000; Ren and Schwartz, 2000). After the pulldown assay, the eluted active RhoA, Rac, or Cdc42 was detected by WB. Total protein was measured in the cell lysates that were used for the pulldown studies and served as loading controls.
###end p 64
###begin title 65
Immunofluorescence and confocal microscopy
###end title 65
###begin p 66
###xml 299 303 <span type="species:ncbi:9925">goat</span>
###xml 855 859 <span type="species:ncbi:9925">goat</span>
###xml 865 870 <span type="species:ncbi:10090">mouse</span>
###xml 933 937 <span type="species:ncbi:9925">goat</span>
###xml 943 949 <span type="species:ncbi:9986">rabbit</span>
Cells were rinsed once in PBS, fixed in 3.7% paraformaldehyde for 15 min at room temperature, and rinsed once in 0.1 M glycine and twice in PBS. The cells were permeabilized in 0.5% Triton X-100 and then washed three times in PBS. Nonspecific sites were blocked by incubation with PBS containing 1% goat serum for 30 min at room temperature before incubating the cells with the primary antibodies diluted in PBS for 3 h at room temperature or overnight at 4degreesC. After four washes in PBS, the cells were incubated with secondary antibodies for 45 min at room temperature, washed three times in PBS, and mounted in VectaShield (Vector Laboratories). F-actin was stained with Texas red-labeled phalloidin (Sigma-Aldrich) for 10 min at room temperature followed by four washes in PBS. The secondary antibodies used include the following: FITC-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories) and FITC-conjugated goat anti-rabbit IgG (heavy light chains; Vector Laboratories). Images of immunolabeled samples were obtained at 20degreesC with a laser-scanning confocal microscope (LSM 510; Carl Zeiss, Inc.) using plan apochromat immersion oil 63x NA 1.4 objective lens and argon ion (488 nm) and HeNe (543 nm) lasers. Images were acquired sequentially by direct register using LSM software (Carl Zeiss, Inc.) without manipulation; for double labeling experiments, images of the same confocal plane were generated and superimposed. Phase-contrast images were captured with a digital camera (DC300; Leica) mounted on an inverted microscope (Labovert FS; Leitz). TIFF images were processed using Photoshop 7.0 software (Adobe).
###end p 66
###begin title 67
Quantitative RT-PCR (qRT-PCR)
###end title 67
###begin p 68
###xml 128 132 128 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 145 160 145 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPN, OCN, CYP3A</italic>
###xml 166 171 166 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 267 271 267 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 346 349 346 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPN</italic>
###xml 413 416 413 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OCN</italic>
###xml 480 485 480 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A</italic>
###xml 551 556 551 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 582 587 582 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 592 595 592 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">18S</italic>
###xml 1017 1038 993 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">Perakyla et al., 2005</xref>
Total RNA was purified using RNeasy mini kits following the manufacturer's instructions (QIAGEN). To measure the RNA levels for CDH1/E-cadherin, OPN, OCN, CYP3A, and GAPDH, we used oligonucleotides (5'-AGAACGCATTGCCACATACACTC-3' and 5'-CATTCTGATCGGTTACCGTGATC-3' for CDH1/E-cadherin; 5'-TTGCAGTGATTTGCTTTTGC-3' and 5'-GTCATGGCTTTCGTTGGACT-3' for OPN; 5'-GCACAGCCCAGAGGGTATAA-3' and 5'-CGCCTGGGTCTCTTCACTAC-3' for OCN; 5'-GATGAAAGAAAGTCGCCTCG-3' and 5'-TGCAGTTTCTGCTGGACATC-3' for CYP3A; 5'-ACAGTCCATGCCATCACTGCC-3' and 5'-CTAGCTGACCTCCTTGACCTG-3' for GAPDH) and SYBR green, and for CYP24 and 18S rRNA, we used TaqMan probes (Applied Biosystems) with a 7900HT fast real-time PCR system (Applied Biosystems). The PCR cycling conditions used were as follows: incubation at 95degreesC for 10 min followed by 40 cycles of 15 s at 95degreesC, 60 s at 60degreesC, and 5 s at 72degreesC. At the end of the PCR cycles, melting curve analyses were performed, and the extent of induction was calculated as described previously (Perakyla et al., 2005).
###end p 68
###begin title 69
Statistical analysis
###end title 69
###begin p 70
###xml 141 142 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
The data are expressed as the mean +/- SD unless otherwise specified. Statistical significance was assessed by two-tailed unpaired student's t test. The single asterisk indicates P < 0.05, the double asterisk P < 0.01, and the triple asterisk P < 0.001. When P > 0.05, the data were considered not significant. All statistical analyses were performed using Instat 3.0 software (GraphPad).
###end p 70
###begin title 71
Online supplemental material
###end title 71
###begin p 72
###xml 138 140 138 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 141 144 141 144 <sub xmlns:xlink="http://www.w3.org/1999/xlink">cyt</sub>
###xml 150 152 150 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 163 164 163 164 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 165 166 165 166 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 422 423 422 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 424 425 424 425 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 554 555 554 555 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 556 557 556 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 925 930 925 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 970 971 970 971 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 972 973 972 973 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1096 1101 1096 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 1103 1106 1103 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPN</italic>
###xml 1112 1117 1112 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP3A</italic>
###xml 1149 1154 1149 1154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP24</italic>
###xml 1177 1178 1177 1178 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1179 1180 1179 1180 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1228 1233 <span type="species:ncbi:9606">human</span>
Fig. S1 shows controls for transcription inhibition by actinomycin D and DRB in SW480-ADH cells and the specificity of the increase of [Ca2+]cyt by 10-7 M 1,25(OH)2D3. Fig. S2 shows the lack of effect of N19-RhoA on VDR expression in SW480-ADH cells and of C3 exoenzyme and Y27632 on E-cadherin expression in SW480-ADH-E-cadherin cells and the dependence on RhoA-ROCK of the induction of claudin-7 and occludin by 1,25(OH)2D3. Fig. S3 shows the inhibition by N19-RhoA and Y27632 of the induction of paxillin, stress fibers, and focal contacts by 1,25(OH)2D3. Fig. S4 shows a scheme of the action of the kinase inhibitors used, their effect on cell viability, on E-cadherin expression and S6K1 phosphorylation (rapamycin), on histone H3 (GF109203X, Ro318220, SB203580, H89, and Rp-cAMP), on MSK (H89, Ro318220, and SB203580), and on cofilin and PRK2 phosphorylation (Ro318220). Additionally, it shows the effect of PD98059 on CYP24 promoter activation induced by 1,25(OH)2D3. Fig. S5 shows the inhibitory effect of Ro318220 and SB203580 on the induction of CREB phosphorylation, the activation of CYP24, OPN, and CYP3A promoters, and the increase of CYP24 RNA levels by 1,25(OH)2D3 in a panel of normal and tumoral cell lines of human and rodent origin. Online supplemental material is available at .
###end p 72
###begin title 73
Supplementary Material
###end title 73
###begin title 74
[Supplemental Material Index]
###end title 74
###begin p 75
We are grateful to those who provided us with materials and to T. Iglesias and L. Gonzalez-Santiago for advice with the kinase and immunoprecipitation studies. We also thank D. Navarro and T. Martinez for their technical assistance and R. Rycroft for his help with the English manuscript.
###end p 75
###begin p 76
This work was supported by the Ministerio de Ciencia e Innovacion (SAF2007-60341), the Ministerio de Sanidad y Consumo (Instituto de Salud Carlos III-Redes Tematicas de Investigacion Cooperativa; RD06/0020/0009), the Comunidad de Madrid (S-GEN-0266/2006), and the European Union (MRTN-CT-2005-019496; NucSys).
###end p 76

